{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:07:07Z","timestamp":1787580427728,"version":"build-2736575974"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2014,4,11]],"date-time":"2014-04-11T00:00:00Z","timestamp":1397174400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0094585","type":"journal-article","created":{"date-parts":[[2014,4,11]],"date-time":"2014-04-11T20:52:04Z","timestamp":1397249524000},"page":"e94585","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":73,"title":["Effect of HDL-Raising Drugs on Cardiovascular Outcomes: A Systematic Review and Meta-Regression"],"prefix":"10.1371","volume":"9","author":[{"given":"Navjot","family":"Kaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avaneesh","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harish","family":"Negi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nusrat","family":"Shafiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpreet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelima","family":"Chadha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,4,11]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijcard.2012.03.127","article-title":"How to control residual cardiovascular risk despite statin treatment: focusing on HDL-cholesterol","volume":"166","author":"S Lim","year":"2013","journal-title":"Int J Cardiol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","article-title":"High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study","volume":"62","author":"T Gordon","year":"1977","journal-title":"Am J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","article-title":"High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies","volume":"79","author":"DJ Gordon","year":"1989","journal-title":"Circulation"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJMoa064278","article-title":"HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events","volume":"357","author":"P Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/0002-8703(88)90220-7","article-title":"The Prospective Cardiovascular Munster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and\/or diabetes mellitus and the relationship to coronary heart disease","volume":"116","author":"G Assmann","year":"1988","journal-title":"Am Heart J"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1161\/01.CIR.0000154555.07002.CA","article-title":"Cardiology patient page. The \u201cgood cholesterol\u201d: high-density lipoprotein","volume":"111","author":"PP Toth","year":"2005","journal-title":"Circulation"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.ahj.2013.05.021","article-title":"Exercise-mediated changes in high-density lipoprotein: impact on form and function","volume":"166","author":"A Blazek","year":"2013","journal-title":"Am Heart J"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1161\/01.CIR.102.19.2347","article-title":"Alcohol consumption raises HDL cholesterol levels by increasing the transport rate of apolipoproteins A-I and A-II","volume":"102","author":"ESER De Oliveira","year":"2000","journal-title":"Circulation"},{"key":"ref9","unstructured":"Mahley RW, Bersot TP (2011) Drug therapy for hypercholesterolemia and dyslipidemia. In: Bruton L, Lazo JS, Parker KL, editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics.Newyork: McGraw Hill Companies. p949."},{"key":"ref10","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/VHRM.S25238","article-title":"Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases","volume":"8","author":"H Shinkai","year":"2012","journal-title":"Vasc Health Risk Manag"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"D Moher","year":"2009","journal-title":"PLoS Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"PJ Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"WE Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease","volume":"102","author":"D Brunner","year":"2000","journal-title":"Circulation"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Safety of anacetrapib in patients with or at high risk for coronary heart disease","volume":"363","author":"CP Cannon","year":"2010","journal-title":"N Engl J Med"},{"key":"ref16","unstructured":"de Faire U, Ericsson CG, Grip L, Nilsson J, Svane B, et al. (1996) Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Eur Heart J 17 Suppl F: 37\u201342."},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"A Keech","year":"2005","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/eurheartj\/ehs019","article-title":"Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial","volume":"33","author":"TF Luscher","year":"2012","journal-title":"Eur Heart J"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMoa070635","article-title":"Effect of torcetrapib on the progression of coronary atherosclerosis","volume":"356","author":"SE Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"HB Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"GG Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(00)04209-4","article-title":"Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study","volume":"357","author":"G Steiner","year":"2001","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins","volume":"110","author":"AJ Taylor","year":"2004","journal-title":"Circulation"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/HCO.0b013e328362059d","article-title":"Recent clinical trials evaluating benefit of drug therapy for modification of HDL cholesterol","volume":"28","author":"RS Wright","year":"2013","journal-title":"Curr Opin Cardiol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jacc.2004.10.031","article-title":"Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials","volume":"45","author":"RS Birjmohun","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"e77049","DOI":"10.1371\/journal.pone.0077049","article-title":"Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis","volume":"8","author":"C Li","year":"2013","journal-title":"PLoS One"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/bjp.2008.229","article-title":"Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone","volume":"154","author":"MJ Forrest","year":"2008","journal-title":"Br J Pharmacol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/sim.1187","article-title":"How should meta-regression analyses be undertaken and interpreted","volume":"21","author":"SG Thompson","year":"2002","journal-title":"Stat Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000346463","article-title":"High-density lipoprotein subfractions\u2014what the clinicians need to know","volume":"124","author":"A Pirillo","year":"2013","journal-title":"Cardiology"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0094585","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T12:53:08Z","timestamp":1648817588000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0094585"}},"subtitle":[],"editor":[{"given":"Christina","family":"Bursill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,4,11]]},"references-count":29,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,4,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0094585","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,11]]}}}